Proteon Therapeutics Garners $45,000,000 Series D Financing Round

  • Feed Type
  • Date
    5/16/2014
  • Company Name
    Proteon Therapeutics
  • Mailing Address
    200 West Street Waltham, MA 02451 USA
  • Company Description
    Proteon Therapeutics is a biopharmaceutical company developing PRT-201, a novel human recombinant protein that permanently dilates segments of blood vessels, blocks vasospasm, and reduces the formation of vascular scarring.
  • Website
    http://www.proteontherapeutics.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $45,000,000
  • Transaction Round
    Series D
  • Proceeds Purposes
    Proceeds will be used to fully fund the first Phase 3 clinical study of PRT-201. Proteon’s lead product, PRT-201, is a recombinant human elastase in development to prolong the patency and reduce the failure of hemodialysis vascular access in patients with chronic kidney disease (CKD).
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy